Authors
Rong Gong, Shilu Peng, Yiran Yang, Danyang Mei, Shilong Jiang, Hongyu Gao, Yan Cheng
Published in
Tissue & cell. Volume 105. Pages 104128. Nov 13, 2026. Epub Nov 13, 2026.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive malignancy lacking actionable therapeutic targets. Intrinsic resistance to tyrosine kinase inhibitor (TKI) therapy remains a major barrier to improving clinical outcomes. Here, we identify adaptor-related protein complex 1 subunit sigma 1 (AP1S1) as an oncogenic regulator and a potential therapeutic vulnerability in TNBC. Through integrated multi-omics profiling and experimental validation, we found that AP1S1 is significantly overexpressed in breast cancer and correlates with advanced clinicopathological features and poor prognosis. Functionally, knockdown of AP1S1 inhibited cell proliferation, induced apoptosis, and triggered cell cycle arrest in vitro and in patient-derived organoids (PDOs). Single-cell RNA sequencing quantitatively confirmed that AP1S1 expression is specifically enriched in malignant cell populations and closely associates with hyperproliferation and stress-response pathways. Molecularly, AP1S1 is involved in a functional network involving both cell cycle progression and the unfolded protein response (UPR), and its high expression correlates with an "immune-desert" microenvironment characterized by depleted effector T cell infiltration. Furthermore, integrating pharmacogenomic analysis with in vitro and PDOs assays, we found that AP1S1 depletion increases the sensitivity of TNBC cells to erlotinib. Collectively, these findings identify AP1S1 as a multifaceted regulator of TNBC aggressiveness and therapy responsiveness, highlighting its potential as a therapeutic target to enhance TKI sensitivity and its association with immune exclusion.
PMID:
43033554
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0